Case Clinic Challenge: A 63-year-old male, relapsed CLL, 17 p deletion, recurrent bulky lymphadenopathy

Hematology-Oncology
Curriculum:
Personalizing Treatment in Chronic Lymphocytic Leukemia
Credits:
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s)
Launch Date:
April 07, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Community-based medical oncologists, hematologists/oncologists, nurse practitioners, advanced practice nurses, nurse navigators, and physician assistants.

Relevant Terms:

Chronic Lymphocytic Leukemia

Jennifer Woyach, MD

Jennifer Woyach, MD
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, OH

Jennifer Woyach, MD
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, OH

Douglas E. Gladstone, MD

Douglas E. Gladstone, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Douglas E. Gladstone, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

​Heather L. Paradis, MSN, ANP‐BC, AOCN

Heather L. Paradis, MSN, ANP‐BC, AOCN
Nurse Practitioner
Oncology/Hematology
Duke University Medical Center
Durham, NC

Heather L. Paradis, MSN, ANP‐BC, AOCN
Nurse Practitioner
Oncology/Hematology
Duke University Medical Center
Durham, NC
1. Identify key prognostic, predictive, and clinical factors that will help to formulate personalized CLL treatment plans. (Physician)
2. Assess key findings from recent clinical trials analyzing approved and emerging therapeutic options to appropriately treat patients with CLL. (Physician)
3. Interpret clinical and laboratory data in order to monitor response according to best practices. (Physician)
4. Use effective patient–healthcare professional communication to engage patients in shared decision‐making about treatment choices. (Physician)
5. Describe the prognostic, predictive, and clinical factors that influence treatment recommendations. (Nurse)
6. Describe the clinical rationale supporting the use of approved and emerging therapeutic options in the treatment of patients with CLL. (Nurse)
7. Apply clinical and laboratory data to monitor patient response to treatment. (Nurse)
8. Formulate appropriate care and counsel for patients and their families as they are engaged in conversations about treatment choices. (Nurse)

This educational activity is jointly provided by Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing.
 
Supported by an educational grant from AbbVie, Inc., and Genentech Inc.
 
Produced by Haymarket Medical Education 
 
Program Description  
Chronic lymphocytic leukemia (CLL) presents as a spectrum of disease that warrants careful diagnostic and prognostic considerations, including immunophenotyping and risk stratification based on multiple molecular markers. Best practices for the diagnosis, prognosis estimations, treatment, and monitoring of a 68-year-old female patient with newly diagnosed CLL are reviewed. Following determination that the patient is high risk with a poor prognosis, treatment options are reviewed using a shared decision-making model.
 
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
 
Full Disclosure Policy Affecting CME/CNE Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the planning committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. 
 
It is the policy of the Institute for Johns Hopkins Nursing to require our continuing nursing education program faculty and planning committee members to disclose any financial relationships with companies providing program funding or manufacturers of any commercial products discussed in the program.
 
Planning Staff Disclosures
No planner has indicated that he/she has any financial interests in or relationships with a commercial entity.

Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
 
Publishing Staff Disclosures
Haymarket Medical Education staff report that they do not have financial relationships with companies providing program funding and/or manufacturers of any commercial products.
 
Accreditation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
 
Credit Designation Statement(s)
Johns Hopkins University School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
This .50-contact hour enduring activity is provided by the Institute for Johns Hopkins Nursing. Contact hours will be awarded for this enduring activity until April 6, 2017. Approval Code: PO103-2016/0161
 
Disclosure of Unlabeled Use
The following author has disclosed that his case will reference unlabeled/unapproved uses of drugs or products:  
 
Neil E. Kay, MD, references ibrutinib, idelalisib, and obinutuzumab.
 
The Johns Hopkins University School of Medicine/Business of Medicine: Improving Health Care Delivery Skills (EM) may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the US Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
 
Disclaimer
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine or the Institute for Johns Hopkins Nursing name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Method of Participation Instructions
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
 
For CME questions, please contact the Johns Hopkins OCME office at (410) 955-2959 or cmenet@jhmi.edu.
 
If you have any questions relating to the CNE accreditation of this activity, please contact IJHN@jhmi.edu.

Privacy Policy
Internet CME Policy
The Office of Continuing Medical Education (OCME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University School of Medicine OCME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. OCME at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine CME program. CME collects only the information necessary to provide you with the services that you request.
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1     
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above